A startup created to develop biocompatible substances to alter the material properties of a myocardial infarct (area affected by a heart attack). In extensive preliminary work, Gorman-Gillespe Structural Heart has demonstrated that stiffening the infarct early after a heart attack can prevent the progression to heart failure. Myostratum leverages the large animal testing facilities and material science capabilities of the GGSH to develop substances that can be delivered via catheters to the heart to prevent and treat heart failure. A patent portfolio protects all related intellectual property.